Objective To investigate the effects of campto adjuvant chemotherapy on serum levels of interleukin -6 (IL-6), interleukin-10 (IL-10) and survival prognosis of patients with colon cancer .Methods A total of 116 patients with colon cancer who were admitted and treated in Department of Oncology of our hospital from January 2014 to January 2015 were randomly divided control group and observation group , with 58 patients in each group .The patients in control group were treated by postoperative FOLFOX6 chemotherapy combined with bevacizumab ,however,the patients in observation group , on the basis of control group , were given oral campto .The serum levels of IL-6, IL-10 were detected by enzyme-linked immunosorbent assay (ELISA) ,moreover, the clinical curative effects,serum parameters and survival prognosis were observed and compared between two groups .Results The overall remission rate and clinical benefit rate in observation group were significantly higher than those in control group (P<0.05).However there were no significant differences in incidence rates of drug adverse reactions between the two groups (P>0.05).Before treatment, there were no significant differences in the serum levels of IL-6,IL-10 between two groups (P>0.05),however, after treatment, the serum levels of IL-6,IL-10 in both groups were obviously lower than those before treatment (P<0.05), moreover,which in observation group were significantly lower than those in control group (P <0.05).After 2-year follow up,the lost follow-up rate was 0,and the survival rate in observation group was obviously higher than that in control group ,however , the relapse rate in observation group was obviously lower than that in control group (P<0.05).Before treatment, there were no significant differences in the life quality scores between two groups (P>0.05),however, after treatment, the life quality scores in both groups were significantly higher than those before treatment (P<0.05),moreover, the scores in observation group were obviously higher than those in control group (P<0.05).Conclusion The campto adjuvant chemotherapy can help to improve clinical curative effects obviously on colon cancer,which can lower the serum levels IL-6,IL-10 to improve survival prognosis of patients , thus,which is worthy using widely in clinical practice .%目的 探讨伊立替康辅助化疗对结肠癌患者血清白细胞介素-6(Interleukin-6,IL-6)、白细胞介素-10(Interleukin-10,IL-10)与生存预后的影响.方法 选取2014年1月至2015年1月肿瘤科住院部结肠癌患者116例,随机分为2组,每组58例.对照组术后采用FOLFOX6方案化疗联合贝伐单抗治疗;观察组在对照组基础上采用伊立替康治疗.采用酶联免疫吸附测定(enzyme-linked immuno sorbent assay,ELISA)检测血清IL-6、IL-10水平,比较2组临床疗效、血清指标与生存预后状况的差异.结果 观察组总缓解率与临床获益率均明显高于对照组,2组比较差异有统计学意义(P<0.05).2组药物不良反应发生率比较差异无统计学意义(P>0.05).治疗前,2组血清IL-6、IL-10水平比较差异无统计学意义(P>0.05),治疗后,2组上述指标均明显低于治疗前(P<0.05),其中观察组上述指标明显低于对照组(P<0.05).随访2年后,失访率0,观察组生存率明显高于对照组,复发率明显低于对照组(P<0.05).治疗前,2组生存质量评分比较差异无统计学意义(P>0.05),治疗后,全部患者上述评分均明显高于治疗前(P<0.05),其中观察组上述评分明显高于对照组(P<0.05).结论 伊立替康辅助化疗有助于明显改善结肠癌患者的临床疗效,通过降低血清IL-6、IL-10水平,从而改善生存预后状况,值得临床推广应用.
展开▼
